Global Information
회사소개 | 문의

위암 : 파이프라인 리뷰

Gastric Cancer - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 232773
페이지 정보 영문 1462 Pages
가격
US $ 2,500 ₩ 2,848,500 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,697,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,545,500 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


위암 : 파이프라인 리뷰 Gastric Cancer - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 1462 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

위암은 위 내막에 발생하는 악성 종양으로, 징후와 증상에는 권태감, 복통, 구토, 체중 감소, 식후 팽만감, 가슴 쓰림, 소화불량 등이 있습니다. 위암을 이환하는 원인으로는 흡연, 악성빈혈, 위용종, 피로리균 감염, 위암 가족력 등을 들 수 있습니다.

위암 치료제 파이프라인 제품의 개요 및 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향 등을 정리하여 전해드립니다.

서론

위암 - 개요

위암 - 치료제 개발

위암 - 치료제 평가

위암 치료제 개발에 참여하고 있는 기업

약제 개요

위암 - 휴지중인 프로젝트

위암 - 개발이 중지된 제품

위암 - 제품 개발 마일스톤

부록

KSA 17.06.12

List of Tables

  • Number of Products under Development for Gastric Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Gastric Cancer - Pipeline by 3SBio Inc, H2 2018
  • Gastric Cancer - Pipeline by AbbVie Inc, H2 2018
  • Gastric Cancer - Pipeline by AbGenomics International Inc, H2 2018
  • Gastric Cancer - Pipeline by Abion Inc, H2 2018
  • Gastric Cancer - Pipeline by Abpro, H2 2018
  • Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2018
  • Gastric Cancer - Pipeline by ADC Therapeutics SA, H2 2018
  • Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Gastric Cancer - Pipeline by Alkermes Plc, H2 2018
  • Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2018
  • Gastric Cancer - Pipeline by Alteogen Inc, H2 2018
  • Gastric Cancer - Pipeline by Ambrx Inc, H2 2018
  • Gastric Cancer - Pipeline by amcure GmbH, H2 2018
  • Gastric Cancer - Pipeline by Amgen Inc, H2 2018
  • Gastric Cancer - Pipeline by ANP Technologies Inc, H2 2018
  • Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H2 2018
  • Gastric Cancer - Pipeline by Argenx SE, H2 2018
  • Gastric Cancer - Pipeline by Array BioPharma Inc, H2 2018
  • Gastric Cancer - Pipeline by Asana BioSciences LLC, H2 2018
  • Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
  • Gastric Cancer - Pipeline by Astellas Pharma Inc, H2 2018
  • Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2018
  • Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
  • Gastric Cancer - Pipeline by Avipep Pty Ltd, H2 2018
  • Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018
  • Gastric Cancer - Pipeline by Bayer AG, H2 2018
  • Gastric Cancer - Pipeline by BeiGene Ltd, H2 2018
  • Gastric Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
  • Gastric Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018
  • Gastric Cancer - Pipeline by Biocon Ltd, H2 2018
  • Gastric Cancer - Pipeline by Bioleaders Corp, H2 2018
  • Gastric Cancer - Pipeline by BioLineRx Ltd, H2 2018
  • Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Gastric Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Gastric Cancer - Pipeline by Camel-IDS NV, H2 2018
  • Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018
  • Gastric Cancer - Pipeline by CARsgen Therapeutics Ltd, H2 2018
  • Gastric Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2018
  • Gastric Cancer - Pipeline by Celgene Corp, H2 2018

List of Figures

  • Number of Products under Development for Gastric Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 15, 85, 103, 12, 108, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 5, 1, 10 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Gastric Cancer - Overview
  • Gastric Cancer - Therapeutics Development
  • Gastric Cancer - Therapeutics Assessment
  • Gastric Cancer - Companies Involved in Therapeutics Development
  • Gastric Cancer - Drug Profiles
  • Gastric Cancer - Dormant Projects
  • Gastric Cancer - Discontinued Products
  • Gastric Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research